M Ghielmini
Long term follow up of patients with follicular lymphoma receiving single agent rituximab at 2 different schedules in trial SAKK 35/98
Martinelli G, Zucca E, Dietrich P, Lohri A, Vorobiof H, Heizmann M, Stahel R, Stupp R, Okkinga E, Hess U, Cerny T, Utiger U, Schmitz S, Ghielmini M. Long term follow up of patients with follicular lymphoma receiving single agent rituximab at 2 different schedules in trial SAKK 35/98. J Clin Oncol 2010; 28:4480-4484.
Jan 1, 2010Long term follow up of patients with follicular lymphoma receiving single agent rituximab at 2 different schedules in trial SAKK 35/98
Jan 1, 2010J Clin Oncol 2010; 28:4480-4484
Martinelli G, Zucca E, Dietrich P Y, Lohri A, Vorobiof H, Heizmann M, Stahel R, Stupp R, Okkinga E, Hess Urs, Cerny Thomas, Utiger U, Schmitz S F, Ghielmini M
A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03
Hitz F, Ghielmini M, Zimmermann D, Bertoni F, Cogliatti S, Peterson J, Simcock M, Mingrone W, von Moos R, Zucca E, Martinelli G, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03. Hematological oncology 2009; 27:154-9.
Sep 1, 2009A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03
Sep 1, 2009Hematological oncology 2009; 27:154-9
Hitz Felicitas, Ghielmini M, Zimmermann D R, Bertoni F, Cogliatti Sergio B., Peterson J, Simcock M, Mingrone W, von Moos R, Zucca E, Martinelli G, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland
Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK)
Ghielmini M, Cerny T, Wernli M, Ketterer N, Lohri A, Stahel R, Martinelli G, Fey M, Cogliatti S, Léger-Falandry C, Leoncini-Franscini L, Salles G, Rufibach K, Schmitz S. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005; 16:1675-82.
Oct 1, 2005Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK)
Oct 1, 2005Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005; 16:1675-82
Ghielmini M, Cerny Thomas, Wernli M, Ketterer N, Lohri A, Stahel R, Martinelli G, Fey M, Cogliatti S, Léger-Falandry C, Leoncini-Franscini L, Salles G, Rufibach K, Schmitz S-F Hsu
Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study
von Rohr A, Tobler A, Betticher D, Cerny T, Fey M, Racine C, Rufener B, Ghielmini M, Zulian G, Konwalinka G, Frickhofen N, Wernli M, Piguet D, Hess U, Tichelli A, Schmitz S, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002; 13:1641-9.
Oct 1, 2002Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study
Oct 1, 2002Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002; 13:1641-9
von Rohr A, Tobler A, Betticher D, Cerny Thomas, Fey M F, Racine C, Rufener B, Ghielmini M, Zulian G, Konwalinka G, Frickhofen N, Wernli M, Piguet D, Hess U, Tichelli A, Schmitz S-F H, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland
Weekly x 4 induction therapy with the anti-CD20 antibody rituximab: effect on circulating t(14;18)(+) follicular lymphoma cells
Pichert G, Stahel R, Schmitter D, Stupp R, Betticher D, Cogliatti S, Cerny T, Hess U, Schmitz S, Ghielmini M. Weekly x 4 induction therapy with the anti-CD20 antibody rituximab: effect on circulating t(14;18)(+) follicular lymphoma cells. Clinical lymphoma 2001; 1:293-7.
Mar 1, 2001Weekly x 4 induction therapy with the anti-CD20 antibody rituximab: effect on circulating t(14;18)(+) follicular lymphoma cells
Mar 1, 2001Clinical lymphoma 2001; 1:293-7
Pichert G, Stahel R A, Schmitter D, Stupp R, Betticher D, Cogliatti S B, Cerny Thomas, Hess U, Schmitz S F, Ghielmini M
The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK)
Ghielmini M, Bertoni F, Schmitter D, Lohri A, Wernli M, Stupp R, Betticher D, Pichert G, Bürki K, Schmitz S, Cerny T. The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000; 11 Suppl 1:123-6.
Jan 1, 2000The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK)
Jan 1, 2000Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000; 11 Suppl 1:123-6
Ghielmini M, Bertoni F, Schmitter D, Lohri A, Wernli M, Stupp R, Betticher D C, Pichert G, Bürki K, Schmitz S F, Cerny Thomas